Pediatric Nephrology

, Volume 26, Issue 11, pp 2031–2039 | Cite as

Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide

  • Deborah J. Stearns-Kurosawa
  • Valta Collins
  • Scott Freeman
  • Diann Debord
  • Kiyotaka Nishikawa
  • Sun-Young Oh
  • Caitlin S. Leibowitz
  • Shinichiro Kurosawa
Original Article

Abstract

Intestinal infection with Shiga toxin (Stx)-producing E.coli is a leading cause of hemolytic uremic syndrome and acute renal injury in otherwise healthy children in the US. Antibiotics are contraindicated and a therapeutic priority is agents that act intracellularly against the bacterial toxins that drive kidney injury. Our aim was to evaluate whether intravenous administration of a cell-permeable peptide (TVP) that binds to Stx2 will reduce disease severity and rescue juvenile baboons from a lethal Stx2 dose (50 ng/kg). TVP (5 mg/kg) was delivered i.v. simultaneously with toxin (prevention protocol) or at 6 or 24 h after toxin with daily 1 mg/kg supplements up to day 4 (rescue protocols). Biomarkers were monitored in blood and urine up to 28 days. TVP therapy resulted in either absence of clinical signs of acute kidney injury and normal urine output (prevention), or delayed and reduced BUN and creatinine levels (rescue) with concomitant survival. Delayed peptide administration significantly reduced thrombocytopenia, but surprisingly did not alter anemia even when monitored for 28 days in rescued survivors. This is the first successful cell-permeable therapeutic that counteracts Stx2 lethality in an animal model, which recapitulates many of the human responses to enteric infection.

Keywords

Shiga toxins Enterohemorrhagic E.coli Hemolytic uremic syndrome Nonhuman primate Acute renal injury 

Notes

Acknowledgements

This work was supported by NIH/NIAID U01AI075386 (S.K.). Baboons were purchased from the Oklahoma Baboon Research Resource at the University of Oklahoma Health Sciences Center supported by NIH P40RR012317 (Gary White, Director).

We gratefully acknowledge Drs. Gary White, Roman Wolf (Comparative Medicine), and Gary Kinasewitz (Pulmonary and Critical Care Medicine) at the University of Oklahoma Health Sciences Center for veterinary support and discussions. We thank Danielle Day for technical support and Lyndianne Joseph for administrative assistance.

Disclosure of conflicts of interest

The authors declare they have no conflict of interest.

References

  1. 1.
    Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073–1086PubMedGoogle Scholar
  2. 2.
    Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI, Bartleson CA, Lewis JH, Barrett TJ, Wells JG, Baron R, Kobayashi J (1994) A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 272:1349–1353PubMedCrossRefGoogle Scholar
  3. 3.
    Fukushima H, Hashizume T, Morita Y, Tanaka J, Azuma K, Mizumoto Y, Kaneno M, Matsuura M, Konma K, Kitani T (1999) Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 41:213–217PubMedCrossRefGoogle Scholar
  4. 4.
    Yoshioka K, Yagi K, Moriguchi N (1999) Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection: experience of an outbreak in Sakai City, 1996. Pediatr Int 41:223–227PubMedCrossRefGoogle Scholar
  5. 5.
    Cooley M, Carychao D, Crawford-Miksza L, Jay MT, Myers C, Rose C, Keys C, Farrar J, Mandrell RE (2007) Incidence and tracking of Escherichia coli O157:H7 in a major produce production region in California. PLoS ONE 2:e1159PubMedCrossRefGoogle Scholar
  6. 6.
    Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI (1997) Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:e12PubMedCrossRefGoogle Scholar
  7. 7.
    Panos GZ, Betsi GI, Falagas ME (2006) Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24:731–742PubMedCrossRefGoogle Scholar
  8. 8.
    Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930–1936PubMedCrossRefGoogle Scholar
  9. 9.
    Kimmitt PT, Harwood CR, Barer MR (2000) Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 6:458–465PubMedCrossRefGoogle Scholar
  10. 10.
    Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160:994–998PubMedCrossRefGoogle Scholar
  11. 11.
    Donohue-Rolfe A, Kondova I, Oswald S, Hutto D, Tzipori S (2000) Escherichia coli 0157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. J Infect Dis 181:1825–1829PubMedCrossRefGoogle Scholar
  12. 12.
    Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB (2003) Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 18:92–96PubMedGoogle Scholar
  13. 13.
    Okuda T, Tokuda N, Si N, Ito M, Ohta M, Kawamura K, Wiels J, Urano T, Tajima O, Furukawa K, Furukawa K (2006) Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 281:10230–10235PubMedCrossRefGoogle Scholar
  14. 14.
    Saxena S, O'Brien A, Ackerman E (1989) Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 264:596–601PubMedGoogle Scholar
  15. 15.
    Keepers TR, Psotka MA, Gross LK, Obrig TG (2006) A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 17:3404–3414PubMedCrossRefGoogle Scholar
  16. 16.
    Proulx F, Turgeon JP, Litalien C, Mariscalco MM, Robitaille P, Seidman E (1998) Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Pediatr Infect Dis J 17:899–904PubMedCrossRefGoogle Scholar
  17. 17.
    Inward CD, Varagunam M, Adu D, Milford DV, Taylor CM (1997) Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch Dis Child 77:145–147PubMedCrossRefGoogle Scholar
  18. 18.
    Bitzan MM, Wang Y, Lin J, Marsden PA (1998) Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 101:372–382PubMedCrossRefGoogle Scholar
  19. 19.
    Lee SY, Lee MS, Cherla RP, Tesh VL (2008) Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol 10:770–780PubMedCrossRefGoogle Scholar
  20. 20.
    Smith WE, Kane AV, Campbell ST, Acheson DW, Cocharn BH, Thorpe CM (2003) Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 71:1497–1504PubMedCrossRefGoogle Scholar
  21. 21.
    Cornick NA, Jelacic S, Ciol MA, Tarr PI (2002) Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis 186:57–63PubMedCrossRefGoogle Scholar
  22. 22.
    Malyukova I, Murray KF, Zhu C, Boedeker E, Kane A, Patterson K, Peterson JR, Donowitz M, Kovbasnjuk O (2009) Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am J Physiol Gastrointest Liver Physiol 296:G78–92PubMedCrossRefGoogle Scholar
  23. 23.
    Nishikawa K, Watanabe M, Kita E, Igai K, Omata K, Yaffe MB, Natori Y (2006) A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J 20:2597–2599PubMedCrossRefGoogle Scholar
  24. 24.
    Watanabe-Takahashi M, Sato T, Dohi T, Noguchi N, Kano F, Murata M, Hamabata T, Natori Y, Nishikawa K (2010) An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect Immun 78:177–183PubMedCrossRefGoogle Scholar
  25. 25.
    Stearns-Kurosawa DJ, Collins V, Freeman S, Tesh VL, Kurosawa S (2010) Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli. Infect Immun 78:2497–2504PubMedCrossRefGoogle Scholar
  26. 26.
    Taylor FB Jr, Tesh VL, DeBault L, Li A, Chang AC, Kosanke SD, Pysher TJ, Siegler RL (1999) Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154:1285–1299PubMedCrossRefGoogle Scholar
  27. 27.
    Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S (2006) Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol 169:433–444PubMedCrossRefGoogle Scholar
  28. 28.
    Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, Tzipori S, Sheoran AS (2008) Intracellular neutralization of Shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun 76:1931–1939PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Q, Donohue-Rolfe A, Krautz-Peterson G, Sevo M, Parry N, Abeijon C, Tzipori S (2009) Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 199:486–493PubMedCrossRefGoogle Scholar
  30. 30.
    Watanabe M, Matsuoka K, Kita E, Igai K, Higashi N, Miyagawa A, Watanabe T, Yanoshita R, Samejima Y, Terunuma D, Natori Y, Nishikawa K (2004) Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 189:360–368PubMedCrossRefGoogle Scholar
  31. 31.
    Oakes RS, Kirkham JK, Nelson RD, Siegler RL (2008) Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 23:1303–1308PubMedCrossRefGoogle Scholar
  32. 32.
    Van Geet C, Proesmans W, Arnout J, Vermylen J, Declerck PJ (1998) Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 54:1324–1330PubMedCrossRefGoogle Scholar
  33. 33.
    Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346:23–32PubMedCrossRefGoogle Scholar
  34. 34.
    Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, Lethagen S (2001) Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 97:3100–3108PubMedCrossRefGoogle Scholar
  35. 35.
    Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, te Loo M, Monnens L, Remuzzi G, Morigi M (2002) Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 62:846–856PubMedCrossRefGoogle Scholar
  36. 36.
    Nestoridi E, Tsukurov O, Kushak RI, Ingelfinger JR, Grabowski EF (2005) Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 3:752–762PubMedCrossRefGoogle Scholar
  37. 37.
    Siegler RL, Pysher TJ, Tesh VL, Denkers ND, Taylor FB (2002) Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome. Pediatr Nephrol 17:1053–1058PubMedCrossRefGoogle Scholar
  38. 38.
    Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED (1994) Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 125:519–526PubMedCrossRefGoogle Scholar
  39. 39.
    Exeni R, Donato H, Rendo P, Antonuccio M, Rapetti MC, Grimoldi I, Exeni A, de Galvagni A, Trepacka E, Amore A (1998) Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome. Pediatr Nephrol 12:226–230PubMedCrossRefGoogle Scholar
  40. 40.
    Pape L, Ahlenstiel T, Kreuzer M, Drube J, Froede K, Franke D, Ehrich JH, Haubitz M (2009) Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial. Pediatr Nephrol 24:1061–1064PubMedCrossRefGoogle Scholar
  41. 41.
    van't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, de Vos AF, van der Poll T (2007) Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 179:7110–7120Google Scholar
  42. 42.
    Kinasewitz GT, Chang AC, Peer GT, Hinshaw LB, Taylor FB Jr (2000) Peritonitis in the baboon: a primate model which stimulates human sepsis. Shock 13:100–109PubMedCrossRefGoogle Scholar
  43. 43.
    Lopez EL, Contrini MM, Devoto S, de Ros MF, Grana MG, Genero MH, Canepa C, Gomez HF, Cleary TG (1995) Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. Pediatr Infect Dis J 14:594–598PubMedCrossRefGoogle Scholar
  44. 44.
    Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M (2010) From cytokines to toll-like receptors and beyond—current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 16:363–373PubMedCrossRefGoogle Scholar
  45. 45.
    Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E (1995) Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 268:F240–250PubMedGoogle Scholar
  46. 46.
    Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RQ (2002) Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50:767–777PubMedCrossRefGoogle Scholar
  47. 47.
    Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656–1662PubMedCrossRefGoogle Scholar
  48. 48.
    Paton AW, Srimanote P, Talbot UM, Wang H, Paton JC (2004) A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 200:35–46PubMedCrossRefGoogle Scholar
  49. 49.
    Schmidt H, Scheef J, Huppertz HI, Frosch M, Karch H (1999) Escherichia coli O157:H7 and O157:H(-) strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. J Clin Microbiol 37:3491–3496PubMedGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Deborah J. Stearns-Kurosawa
    • 1
  • Valta Collins
    • 1
  • Scott Freeman
    • 1
  • Diann Debord
    • 1
  • Kiyotaka Nishikawa
    • 2
  • Sun-Young Oh
    • 1
  • Caitlin S. Leibowitz
    • 1
  • Shinichiro Kurosawa
    • 1
  1. 1.Department of Pathology and Laboratory MedicineBoston University School of MedicineBostonUSA
  2. 2.Faculty of Life and Medical SciencesDoshisha UniversityKyotoJapan

Personalised recommendations